Current trends in pharmaceutical treatment of dry eye disease: A review
- PMID: 35568107
- DOI: 10.1016/j.ejps.2022.106206
Current trends in pharmaceutical treatment of dry eye disease: A review
Abstract
Dry eye disease (DED), keratoconjunctivitis sicca or dysfunctional tear syndrome, is the most prevalent ophthalmic disease which affects a substantial segment of people worldwide with increasing frequency. It is considered a multifactorial disease of the ocular surface and tear film, characterized by a variation of signs and symptoms. The symptoms range from mild to severe itching, burning, irritation, eye fatigue, and ocular inflammation that may lead to potential damage to the cornea, conjunctiva and even vision loss. Correspondingly, depending on the different manifestations and pathophysiology, the treatment must be tailored specifically to each patient by targeting the specific mechanisms implicated in their disease. Currently, there are several medical products and techniques available or under investigation for the treatment of DED. The present article focused on the pathophysiology of DED, the new diagnostic approach and the recently developed drug delivery systems or devices reducing the progress of the disease and treating the causes.
Keywords: Dry eye disease; Nanomedicine; New diagnostic techniques; New treatment; Ocular delivery system; Ocular devices.
Copyright © 2022. Published by Elsevier B.V.
Similar articles
-
Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.Ann Med. 2023 Dec;55(1):241-252. doi: 10.1080/07853890.2022.2157477. Ann Med. 2023. PMID: 36576348 Free PMC article. Review.
-
The Role of Nano-ophthalmology in Treating Dry Eye Disease.Pharm Nanotechnol. 2020;8(4):258-289. doi: 10.2174/2211738508666200628034227. Pharm Nanotechnol. 2020. PMID: 32600244 Review.
-
[A new approach for better comprehension of diseases of the ocular surface].J Fr Ophtalmol. 2007 Mar;30(3):239-46. doi: 10.1016/s0181-5512(07)89584-2. J Fr Ophtalmol. 2007. PMID: 17417148 French.
-
Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis.Handb Exp Pharmacol. 2017;242:97-118. doi: 10.1007/164_2016_73. Handb Exp Pharmacol. 2017. PMID: 27913889
-
A review of diagnostic tests for qualitative and quantitative tear film deficiency in dogs.Vet Ophthalmol. 2023 Apr;26 Suppl 1:5-15. doi: 10.1111/vop.13044. Epub 2022 Dec 27. Vet Ophthalmol. 2023. PMID: 36575128 Review.
Cited by
-
Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments.Ophthalmol Ther. 2024 Jan;13(1):251-266. doi: 10.1007/s40123-023-00833-7. Epub 2023 Nov 10. Ophthalmol Ther. 2024. PMID: 37948015 Free PMC article.
-
Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells.Curr Issues Mol Biol. 2022 Sep 22;44(10):4415-4438. doi: 10.3390/cimb44100303. Curr Issues Mol Biol. 2022. PMID: 36286018 Free PMC article.
-
Patient-reported outcomes of serum eye drops manufactured from Australian blood donations and packaged using Meise vials.Front Med (Lausanne). 2023 Sep 5;10:1252688. doi: 10.3389/fmed.2023.1252688. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37731710 Free PMC article.
-
In-Situ Thermoresponsive Hydrogel Containing Resveratrol-Loaded Nanoparticles as a Localized Drug Delivery Platform for Dry Eye Disease.Antioxidants (Basel). 2023 Apr 25;12(5):993. doi: 10.3390/antiox12050993. Antioxidants (Basel). 2023. PMID: 37237859 Free PMC article.
-
Navigating dry eye relief: Meibo's approach to controlling tear evaporation.Ann Med Surg (Lond). 2024 Sep 10;86(10):5680-5684. doi: 10.1097/MS9.0000000000002550. eCollection 2024 Oct. Ann Med Surg (Lond). 2024. PMID: 39359802 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
